Clinical Trial

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).
Protocol Amendment History 2 changes
notable Trial sites expanded: 15 -> 27 locations 2026-08-04
notable Trial sites expanded: 10 -> 15 locations 2026-06-13
Trial Details
NCT Number NCT07611214
Lead Sponsor Aurinia Pharmaceuticals Inc.
Conditions Lupus Nephritis
Enrollment 150 participants
Start Date 2026-04-22
Primary Completion 2029-03-02 (estimated)
Study Completion 2029-03-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-03